Edguider Online Blog on ED, viagra, cialis and levitra

Topically applied Vitaros ED cream by Apricus Biosciences

A topically applied erectile therapy cream is one step closer to reality. The commercial launch of Vitaros by Apricus Biosciences, the world’s first topically applied prescription drug for impotence, is scheduled for November of this year in Canada. The cream is also likely to reach European pharmacy shelves by the end of next year.

With annual erectile dysfunction drug sales at $4.9 billion globally and an aging population, translating into increasing demand, any newcomer on the impotence market has the chance of making it big. Vitaros in particular is a promising competitor, having two major innovations going for it: its topical application and its uncommon active ingredient.

One Drop of Vitaros will work in about 6 minutes!

With a single-use applicator a drop of Vitaros is placed on the tip of the penis. The active ingredient, PDE1, also known as alprostadil, is then absorbed through the skin through Vitaros’s high absorption molecules. The effects are measurable within six minutes. Because alprostadil works differently from the PDE5-inhibitors in most common impotence pills it could be a viable alternative for those who have tried other therapies with limited success. The topical application is also associated with fewer side-effects. Alprostadil is currently available as penile injections (Caverject) and urethral suppositories, but having the chemical absorbed through the skin is no doubt more pleasant.

EDGuider News: Vitaros ED Cream by Apricus Bio Works Within 5 Minutes

In its current formula, Vitaros has one major setback: it must be stored in a refrigerator. That makes sex less spontaneous and travel more difficult. Apricus is aware of this and is currently working on developing a new formula that can be stored in room temperature.

How much will Vitaros Cost?

As for the price, Vitaros is expected to enter the market at between $10 and $12 per dose, similar to competitors.

Whether Vitaros will be a major success, though, remains to be seen. Expert opinions diverge: “I think it can certainly enter the market as a fourth or fifth drug and grow sales significantly,” said Robert Wasserman, a Dawson James Securities stock analyst. Dr. Irwin Goldstein, a San Diego urologist who helped develop Viagra, on the other hand believes that Vitaros will enter the market as a niche treatment.

EDGuider Forum: Talk about Vitaros with others

Regardless of the experts, there is no denying that Apricus takes its entry onto the sexual dysfunctions market seriously. The company is already in phase three clinical testing of a new drug called Femprox to treat sexual arousal disorder in women.